Article thumbnail

Host and Viral Genetic Correlates of Clinical Definitions of HIV-1 Disease Progression

By Concepción Casado, Sara Colombo, Andri Rauch, Raquel Martínez, Huldrych F. Günthard, Soledad Garcia, Carmen Rodríguez, Jorge del Romero, Amalio Telenti and Cecilio López-Galíndez
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2009). A combination of defective DNA and protective host factors are found in a set of HIV-1 ancestral LTNPs.
  2. (1998). A new classification for HIV-1.
  3. (2006). A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences.
  4. (2005). A subset of human immunodeficiency virus type 1 long-term non-progressors is characterized by the unique presence of ancestral sequences in the viral population.
  5. (2007). A WholeGenome Association Study of Major Determinants for Host Control of HIV-1. Science.
  6. (2009). CCL3L1 and HIV/AIDS susceptibility.
  7. (2009). Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study.
  8. (2009). Common genetic variation and the control of HIV-1 in humans.
  9. (2009). Common variants at 30 loci contribute to polygenic dyslipidemia.
  10. (1999). Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.
  11. (2009). Continuous Viral Escape and Selection by Autologous Neutralizing Antibodies in Drug-Naive Human Immunodeficiency Virus Controllers.
  12. (2009). Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.
  13. (2009). Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics.
  14. (2009). Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.
  15. (2007). Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape.
  16. (2008). Genetic and Immunologic Heterogeneity among Persons Who Control HIV Infection in the Absence of Therapy. J Infect Dis.
  17. (2005). HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.
  18. (2003). HIV RNA in plasma rebounds within days during structured treatment interruptions.
  19. (2008). HLA class Irestricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for longterm virus control.
  20. (2009). HLA-Associated Alterations in Replication Capacity of Chimeric NL4-3 Viruses Carrying gag-protease from Elite Controllers of Human Immunodeficiency Virus Type 1.
  21. (2007). Lack of temporal structure in the short term HIV-1 evolution within asymptomatic naive patients.
  22. (2005). Low Human Immunodeficiency Virus Envelope Diversity Correlates with Low In Vitro Replication Capacity and Predicts Spontaneous Control of Plasma Viremia after Treatment Interruptions.
  23. (2009). Natural control of HIV-1 replication and long-term nonprogression:overlappingbutdistinctphenotypes.JInfectDis200:1636–1638.
  24. (2009). Persistent Low Level Viremia in HIV-1 Elite Controllers and Relationship to Immunologic Parameters. J Infect Dis.
  25. (2004). Plasma RNA viral load is not associated with intrapatient quasispecies heterogeneity in HIV-1 infection.
  26. (2009). Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV.
  27. (1999). Racespecific HIV-1 disease-modifying effects associated with CCR5 haplotypes.
  28. (1993). Relation of phenotype evolution of HIV-1 to envelope V2 configuration.
  29. (1997). Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.